No profile data available.
Prothena Corporation plc (PRTA) is a healthcare company in the brain and nerve treatment drugs industry, based in Dublin, Ireland, with about 67 full-time employees.
It reported revenue of $135.16 million for fiscal year 2024, up 47.9% from fiscal year 2023, and net income of -$122.31 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $2.42 million, up 149.0% from a year before. Its market capitalization was $453.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Prothena reported $135.16 million in revenue for fiscal year 2024, up 47.9% from $91.37 million in fiscal year 2023. In Q3 2025 revenue was $2.42 million.
$453.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Neurogene Inc. (NGNE), Ovid Therapeutics Inc. (OVID), Capricor Therapeutics, Inc. (CAPR), Relmada Therapeutics, Inc. (RLMD).